Insulin secretory defect and insulin resistance in isolated impaired fasting glucose and isolated impaired glucose tolerance by Aoyama-Sasabe, Sae et al.
Title
Insulin secretory defect and insulin resistance in isolated
impaired fasting glucose and isolated impaired glucose
tolerance
Author(s)
Aoyama-Sasabe, Sae; Fukushima, Mitsuo; Xin, Xin;
Taniguchi, Ataru; Nakai, Yoshikatsu; Mitsui, Rie; Takahashi,
Yoshitaka; Tsuji, Hideaki; Yabe, Daisuke; Yasuda, Koichiro;
Kurose, Takeshi; Inagaki, Nobuya; Seino, Yutaka




Copyright © 2016 Sae Aoyama-Sasabe et al. This is an open
access article distributed under the Creative Commons
Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the





Insulin Secretory Defect and Insulin Resistance in
Isolated Impaired Fasting Glucose and Isolated Impaired
Glucose Tolerance
Sae Aoyama-Sasabe,1 Mitsuo Fukushima,1,2 Xin Xin,3 Ataru Taniguchi,4
Yoshikatsu Nakai,5 Rie Mitsui,6 Yoshitaka Takahashi,7 Hideaki Tsuji,7 Daisuke Yabe,8,9
Koichiro Yasuda,10 Takeshi Kurose,8,9 Nobuya Inagaki,11 and Yutaka Seino8,9
1 Division of Clinical Nutrition and Internal Medicine, Okayama Prefectural University, Okayama 719-1197, Japan
2 Preemptive Medicine and Lifestyle-Related Disease Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan
3 Faculty of Computer Science and Systems Engineering, Okayama Prefectural University, Okayama 719-1197, Japan
4 Division of Diabetes and Endocrinology, Kyoto Preventive Medical Center, Kyoto 604-8491, Japan
5 Kyoto Institute of Health Science, Kyoto 604-0845, Japan
6 Center for Preventive Medicine, St. Luke’s International Hospital, Tokyo 104-6591, Japan
7 Faculty of Health and Welfare Science, Okayama Prefectural University, Okayama 719-1197, Japan
8 Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka 553-0003, Japan
9 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute,
Kobe 650-0047, Japan
10Department of Diabetes and Endocrinology, Saiseikai Noe Hospital, Osaka 536-0001, Japan
11Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
Correspondence should be addressed to Mitsuo Fukushima; fukushima7788@yahoo.co.jp
Received 21 June 2015; Accepted 18 August 2015
Academic Editor: Konstantinos Kantartzis
Copyright © 2016 Sae Aoyama-Sasabe et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective.To investigate the characteristics of isolated impaired glucose tolerance (IGT) and isolated impaired fasting glucose (IFG),
we analyzed the factors responsible for elevation of 2-hour postchallenge plasma glucose (2 h PG) and fasting plasma glucose (FPG)
levels. Methods. We investigated the relationship between 2 h PG and FPG levels who underwent 75 g OGTT in 5620 Japanese
subjects at initial examination for medical check-up. We compared clinical characteristics between isolated IGT and isolated IFG
and analyzed the relationships of 2 h PG and FPG with clinical characteristics, the indices of insulin secretory capacity, and insulin
sensitivity. Results. In a comparison between isolated IGT and isolated IFG, insulinogenic index was lower in isolated IGT than that
of isolated IFG (0.43 ± 0.34 versus 0.50 ± 0.47, resp.; 𝑝 < 0.01). ISI composite was lower in isolated IFG than that of isolated IGT
(6.87 ± 3.38 versus 7.98 ± 4.03, resp.; 𝑝 < 0.0001). In isolated IGT group, insulinogenic index showed a significant correlation with
2 h PG (𝑟 = −0.245, 𝑝 < 0.0001) and had the strongest correlation with 2 h PG (𝛽 = −0.290). In isolated IFG group, ISI composite
showed a significant correlation with FPG (𝑟 = −0.162, 𝑝 < 0.0001) and had the strongest correlation with FPG (𝛽 = −0.214).
Conclusions.We have elucidated that decreased early-phase insulin secretion is the most important factor responsible for elevation
of 2 h PG levels in isolated IGT subjects, and decreased insulin sensitivity is the most important factor responsible for elevation of
FPG levels in isolated IFG subjects.
1. Introduction
Impaired glucose tolerance (IGT) and impaired fasting glu-
cose (IFG) are the different categories of abnormal glucose
metabolism in the early stage development of type 2 diabetes.
Two-hour PG elevation keeps steps with FPG elevation;
however, the individuals showing dominant elevation of 2 h
PG and showing dominant elevation of FPG exist. Elevation
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of 2 h PG and FPG levels are regulated by insulin secretory
capacity and insulin sensitivity, but it is still controversial
which factors are responsible for initial elevation of 2 h PG
and FPG levels in the early stage development of type 2
diabetes. There were a few studies that directly compared
pathophysiology between isolated IGT and isolated IFG to
elucidate the differences of metabolic abnormality (isolated
IGT is a subgroup of impaired glucose regulation showing
only dominant elevation of 2 h PG, defined as FPG <
100mg/dL within the normal range and 2 h PG 140–
199mg/dL within the range of borderline; isolated IFG is
a subgroup of impaired glucose regulation showing only
dominant elevation of FPG, defined as FPG 100–125mg/dL
within the range of borderline and 2 h PG < 140mg/dL
within the normal range), but it is not conclusive yet because
the study conditions are different in subjects’ ethnicity and
methods examined. Weyer et al. reported isolated IFG and
isolated IGT showed a similar impairment in insulin action
but isolated IFG showed remarkable defect in early-phase
insulin secretion in Pima Indian [1]. Festa et al. demonstrated
that isolated IGTwasmore insulin resistant than isolated IFG
in three ethnic populations: non-Hispanic whites, African
Americans, and Hispanics [2]. We reported that impaired
early-phase insulin secretion plays the more important role
in deterioration from normal glucose tolerance (NGT) via
isolated IGT to isolated postchallenge hyperglycemia (IPH)
in Japanese [3]. In Korean subjects, pathogenesis of isolated
IFG was associated with insulin resistance and isolated IGT
was associated with impaired insulin secretion [4]. It is to
be discussed whether decreased insulin secretory capacity
and/or decreased insulin sensitivity play critical roles in the
dominant elevation of 2 h PG and FPG levels in the early stage
development of type 2 diabetes. Several studies have reported
that there are some differences in atherogenic factors, such
as triglyceride and apolipoprotein B and progression of
atherosclerosis between subjects with IGT and IFG [5–10].
Previous epidemiological studies demonstrated that IGT has
a higher risk for death from cardiovascular disease (CVD)
compared with IFG [11–13]. Thus, it is also important to
discuss the similarities and differences between isolated IGT
and isolated IFG in view of future development of diabetic
complications.
In the present study, we directly compared the clinical
characteristics between isolated IGT and isolated IFG sub-
jects and investigated the factors responsible for dominant
elevation of 2 h PG and FPG levels in the prediabetic pop-
ulation. From the OGTT examinations, we divided subjects
into subgroups by glucose tolerance, that is, isolated IGT and
isolated IFG subjects, and compared the clinical parameters,
indices of insulin secretory capacity, and insulin sensitivity.
To determine the primary factors elevating 2 h PG or FPG
levels in isolated IGT and isolated IFG groups, respectively,
we analyzed the relationships between 2 h PG and clinical
parameters in isolated IGT and between FPG levels and
clinical parameters in isolated IFG subjects.
2. Subjects and Methods
We studied a total of 5620 cases who underwent 75 g
oral glucose tolerance test (OGTT) owing to positive urine
glucose test, >5.5% HbA1c level, >100mg/dL fasting plasma
glucose level, or family history of diabetes at initial exam-
ination for medical check-up from 1993 to 2013. From the
beginning of 5620 individuals, 715 subjects were excluded
because of FPG levels < 60mg/dL, ≧126mg/dL or 2 h PG
levels < 60mg/dL, ≧200mg/dL for this study to analyze
the factors in the early stage development of type 2 dia-
betes, having hypertension, hepatic, pancreatic, or renal
dysfunction, endocrine or malignant disease, or history of
heavy exercise, gastrectomy, or medication known to affect
glucose metabolism, and 4905 subjects were included finally.
This study was a cross-sectional, multicenter study at Kyoto
University Hospital, Ikeda Hospital, Kansai Electric Power
Hospital, Kansai Health Management Center, Center for
Preventive Medicine of St. Luke’s International Hospital, and
Kyoto Preventive Medical Center.
We obtained fasting, 30, 60, and 120 min blood samples
after oral administration of 75 g glucose for measurement
of clinical parameter, plasma glucose, and serum insulin
levels during 75 g OGTT. Standard OGTT with 75 g glucose
was administered according to the National Diabetes Data
Group recommendations [14], which require subjects to fast
overnight for 10 to 16 hours before blood collection. We
measured HbA1c, total-cholesterol, high-density lipoprotein
cholesterol (HDL-cholesterol), and triglyceride (TG) levels.
Plasma glucose level was measured by glucose oxi-
dase method using Hitachi Automatic Clinical Analyzer
7170 (Hitachi Co. Ltd., Tokyo, Japan). Serum insulin level
was measured by chemiluminescent immunoassay (ARCHI-
TECT insulin assay, Abbot Laboratories, Abbot Park, IL).
Serum total-cholesterol and triglycerides levels were deter-
mined as reported previously [15]. HbA1c value, estimated as
an NGSP equivalent value, was calculated by the following
formula: HbA1c (JDS) + 0.4%. HbA1c was measured by
HLC-723G7 (Tosoh, Tokyo, Japan) following the previous
Japanese standard measurement methods [16]. Early-insulin
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Table 1: Clinical characteristics of subjects.
NFG/NGT Isolated IFG Isolated IGT IFG/IGT
Number (M/F) 2046 (1012/1034) 1510 (1098/412) 396 (210/186) 953 (718/235)
Age (yr)∗ 53.0 ± 12.1 55.5 ± 10.0 57.1 ± 10.8 57.0 ± 9.9
BMI (kg/m2)∗∗ 22.1 ± 3.0 23.5 ± 3.1 22.9 ± 3.3 24.3 ± 3.3
FPG (mg/dL)∗∗ 91.0 ± 5.8 106.7 ± 5.6 93.2 ± 5.2 108.8 ± 6.4
2 h PG (mg/dL)∗ 106.3 ± 18.0 112.8 ± 17.4 158.8 ± 15.2 164.0 ± 17.0
Fasting insulin (𝜇U/mL)∗ 4.6 ± 2.2 6.0 ± 3.4 5.1 ± 2.8 7.0 ± 4.3
HbA1c (%)∗ 5.80 ± 0.40 5.83 ± 0.43 5.93 ± 0.41 5.98 ± 0.44
Triglycerides (mg/dL) 91.4 ± 49.2 110.9 ± 61.0 105.5 ± 54.4 132.1 ± 73.9
Total-cholesterol (mg/dL) 208.7 ± 31.2 209.5 ± 31.2 209.5 ± 28.7 213.6 ± 31.5
HDL-cholesterol (mg/dL) 65.1 ± 16.1 61.9 ± 16.8 62.5 ± 16.0 57.6 ± 15.6
Clinical characteristics of subjects grouping by stage of glucose tolerance are listed. Data are mean ± SD. ∗𝑝 < 0.05 and ∗∗𝑝 < 0.0001 in ANOVA between
isolated IGT and isolated IFG.
expressed as the multiplex of the indices of insulin secretion
and insulin sensitivity and calculated using the following
formula: Insulinogenic index × ISI composite [20].
All subjects were divided into four subgroups according
to the ADA criteria, with normal fasting glucose with normal
glucose tolerance (NFG/NGT), FPG < 100mg/dL, and 2 h PG
< 140mg/dL; isolated IFG, FPG 100–125mg/dL, and 2 h PG <
140mg/dL; isolated IGT, FPG < 100mg/dL, and 2 h PG 140–
199mg/dL; IFG with IGT (IFG/IGT), FPG 100–125mg/dL,
and 2 h PG 140–199mg/dL [21].
Simple linear regression analysis was conducted for all
subjects to investigate the associations between 2 h PG in
isolated IGT subjects or FPG levels in isolated IFG subjects
and the other clinical factors such as age, BMI, plasma glu-
cose level, serum insulin level, HbA1c, TG, total-cholesterol,
HDL-cholesterol, insulinogenic index, and ISI composite in
IFG/IGT subjects. ANOVAandBonferroni post hoc test were
used to compare differences between groups and 𝑝 < 0.05
was considered as statistically significant. We carried out
multivariate regression analysis to identify the independent
predictors of 2 h PG in isolated IGT subjects or FPG levels
in isolated IFG subjects and evaluated variables with 𝛽, and
𝑝 < 0.05 was considered as statistically significant. All
statistical analyses were performed using SPSS version 14.0
(SPSS, Chicago, IL). All data are shown in mean ± SD.
3. Results
3.1. Clinical Characteristics of Subjects. The subjects were
4905 in total (3038/1867; males/females); NGT, 2046
(1012/1034); isolated IFG, 1510 (1098/412); isolated IGT,
396 (210/186); IFG/IGT, 953(718/235), according to ADA
criteria [21]. The mean age of the subjects was 54.8 ± 11.1
years, and BMI was 23.0 ± 3.2 kg/m2. Parameters for glucose
metabolism as the mean FPG, 2 h PG levels, and HbA1c were
99.5 ± 10.0mg/dL, 123.7 ± 29.7, and 5.95 ± 0.42, respectively.
3.2. Clinical Characteristics of SubjectGroupswith Isolated IFG
or Isolated IGT. Comparison of the clinical and metabolic
characteristics between isolated IFG (𝑛 = 1510) and isolated
IGT (𝑛 = 396) groups is shown in Table 1. FPG, BMI, and
fasting insulin were significantly higher in isolated IFG group
than those in isolated IGT group (𝑝 < 0.0001). Two-hour
PG, age, and HbA1c were significantly higher in isolated
IGT group than those in isolated IFG group (𝑝 < 0.05).
Two groups did not differ significantly in triglyceride, total-
cholesterol, and HDL-cholesterol. Area under the curve of
glucose (AUC-glucose) was significantly higher in isolated
IGT subjects but area under the curve of insulin (AUC-
insulin) of isolated IGT was significantly lower than that
of isolated IFG (data not shown). Figure 2 shows the com-
parison of insulin secretory capacity and insulin sensitivity.
The insulinogenic index representing for early-phase insulin
secretory capacity during 0–30min after glucose load was
significantly lower in isolated IGT group than that in isolated
IFG group (0.43 ± 0.34 versus 0.50 ± 0.47, resp.; 𝑝 <
0.01), when these groups were directly compared. The ISI
composite representing for whole-body insulin sensitivity
was significantly lower in isolated IFG group than that in
isolated IGT group (6.87 ± 3.38 versus 7.98 ± 4.03, resp.; 𝑝 <
0.0001). The HOMA-IR was significantly higher in isolated
IFG group than that in isolated IGT group (1.58±0.92 versus
1.19 ± 0.66, resp.; 𝑝 < 0.0001). There was no significant
difference in disposition index between isolated IGT and
isolated IFG groups (2.94 ± 2.49 versus 2.92 ± 2.80, resp.;
𝑝 = 0.68).
3.3. The Relationship of 2 h PG and FPG with Factors Respon-
sible for Glucose Intolerance. The simple linear regression
analysis between FPG (𝑦-axis) and 2 h PG (𝑥-axis) is shown
in Figure 1. The resulting regression line was an equation
of the first degree written as 𝑦 = 0.119𝑥 + 84.70 (𝑟 =
0.355). Table 2 shows the relationship of 2 h PG in IGT
subjects and FPG in IFG subjects with factors responsible
for glucose intolerance evaluated by simple linear regression
analysis andmultivariate regression analysis. In IGT subjects,
insulinogenic index showed significant correlationship with
2 h PG levels in simple linear regression analysis and the
highest𝛽-value among independent variables associatedwith
2 h PG levels (𝛽 = −0.290, 𝑝 < 0.0001). In IFG subjects,
ISI composite, insulinogenic index, BMI, and TG showed
significant correlationship with FPG levels in simple linear
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Table 2: Factors responsible for elevating FPG levels in isolated IFG and 2 h PG levels in isolated IGT.
Variable Simple linear regression analysis Multivariate regression analysis
Correlation coefficient 𝑝 value 𝛽-value 𝑝 value
2 h PG levels as a dependent variable in isolated IGT
Insulinogenic index −0.245 𝑝 < 0.0001 −0.290 𝑝 < 0.0001
ISI composite −0.015 ns −0.097 ns
Age 0.043 ns 0.077 ns
Triglycerides 0.032 ns 0.053 ns
BMI 0.008 ns 0.007 ns
FPG levels as a dependent variable in isolated IFG
ISI composite −0.162 𝑝 < 0.0001 −0.214 𝑝 < 0.0001
Insulinogenic index −0.111 𝑝 < 0.0001 −0.184 𝑝 < 0.0001
BMI 0.092 𝑝 < 0.0005 0.042 ns
Triglycerides 0.058 𝑝 < 0.05 0.038 ns
Age 0.028 ns 0.006 ns


















Figure 1: Simple linear regression line between 2 h PG and FPG
levels based on least square method is indicated by solid line (𝑦 =
0.119𝑥+84.70).There was a positive correlation between 2 h PG and
FPG significantly (𝑟 = 0.355, 𝑝 < 0.0001).
regression analysis and ISI composite showed the highest
𝛽-value among independent variables associated with FPG
levels (𝛽 = −0.214, 𝑝 < 0.0001) and insulinogenic index is
the second only to ISI composite (𝛽 = −0.184, 𝑝 < 0.0001).
4. Discussion
We examined the clinical characteristics of isolated IGT and
isolated IFG in view of insulin secretory capacity and insulin
sensitivity. In isolated IGT group, we have elucidated that
early-phase insulin secretory capacitywas the strongest factor
to determine 2 h PG levels. Early-phase insulin secretory
capacity of isolated IGT group was significantly lower than
that of isolated IFG group. In isolated IFG group, insulin
sensitivity was the strongest factor to determine FPG levels
and early-phase insulin secretory capacity was also a strong
factor to affect FPG levels next to insulin sensitivity. In
isolated IFG group, insulin sensitivity was lower than that in
isolated IGT group.
Different pathophysiology between isolated IGT and
isolated IFGhas been discussed but it is still under discussion.
Controversial evidences in the previous studies may be
because there are different characteristics of subjects includ-
ing ethnicity and population of the subjects. In a Caucasian
study, isolated IGT showingmore decreased insulin secretion
than isolated IFG, isolated IFG was more insulin resistant
than isolated IGT [22]. In Pima Indian, non-Hispanic whites,
African Americans, and Hispanics, isolated IGT was more
insulin resistant than isolated IFG [1, 2]. But in Japanese
and Korean, impaired early-phase insulin secretion plays the
more important role in isolated IGT and insulin resistance
plays more important role in isolated IFG subjects [3, 4, 23].
Another study reported that isolated IGT was characterized
by both impaired insulin secretion and insulin resistance,
but there are no significant differences in insulin sensitivity
between isolated IFG and isolated IGT (𝑛 = 128, 𝑛 = 55,
resp.) subjects [24]. In the present study, we have elucidated
the significant difference between isolated IGT and isolated
IFG with large number of subjects. Early-phase insulin
secretory capacity was lower in isolated IGT subjects than
that in isolated IFG and insulin sensitivity was lower in
isolated IFG subjects than that in isolated IGT subjects. Our
data directly compared isolated IGT with isolated IFG and
revealed for the first time the different characteristics of
isolated IGT and isolated IFG in aspects of insulin secretory
capacity and insulin sensitivity in Japanese.
Individuals with isolated IGT and isolated IFG both
have higher risk for the development of type 2 diabetes
than NFG/NGT [25]. However, large observational studies
revealed that isolated IGT have higher CVD risk than isolated
IFG [11–13]. In European study within NFG/NGT categories,
elevated 2 h PG group (2 h PG levels were higher than FPG
levels) showed higher mortality from CVD than the indi-
viduals whose 2 h PG returned to their FPG levels or lower
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Figure 2: (a), (b), (c) Comparison of early-phase insulin secretory capacity (a), insulin sensitivity (b), and disposition index (c) among
NFG/NGT, isolated IFG, and isolated IGT. Statistical significance between two groups was represented as ∗: 𝑝 < 0.05, ∗∗∗: 𝑝 < 0.0001, and
n.s.: not significant.
[26]. In Japanese study within NFG/NGT, Morimoto et al.
revealed that impaired insulin secretion group had a greater
impact on the incidence of type 2 diabetes compared with
insulin resistance group by large-scale prospective cohort
study [27]. In the present study, early-phase insulin secretory
capacity and AUC-insulin of isolated IGT were significantly
lower than those of isolated IFG, andAUC-glucose of isolated
IGT was significantly higher than that of isolated IFG. These
results indicate that aggressive prevention of 2 h PG elevation
is required from the aspects of complication and development
of type 2 diabetes focusing on isolated IGT with stronger
impairment of insulin secretion and glucose tolerance.
Two-hour PG levels showed the highest association with
insulinogenic index in isolated IGT group in multivariate
regression analyses. Fearch et al. concluded that a progressive
and age-dependent loss of insulin secretion was involved in
the development of postchallenge hyperglycemia in relation
to progression from NGT to isolated IGT by 5-year follow-
up study [28]. There are additional studies that reported that
the main factors responsible for elevation of 2 h PG levels
6 Journal of Diabetes Research
were decreased early-phase insulin secretion linked to aging
[8, 29–31]. IGT subjects showed a larger decrease in insulin
secretion compared with NGT subjects and early-phase was
decreasing more than second-phase of insulin secretion [29].
When we compared isolated IGT and isolated IFG group,
early-phase insulin secretion of isolated IGT group was
lower than isolated IFG group, and mean age of isolated
IGT group was higher than isolated IFG group. Together
with these observations, age dependent 𝛽-cell dysfunction
is possibly associated with decreased early-phase insulin
secretion finally resulting in 2 h PG elevation.
FPG levels showed the highest association with ISI com-
posite in isolated IFG group and secondly with insulinogenic
index in multivariate regression analyses. Prospective study
reported that insulin sensitivity in isolated IFG subjects was
significantly reduced compared with that in NGT subjects
prior to the development and diagnosis of isolated IFG
[28, 32–34]. In this study, insulin sensitivity was lower in
isolated IFG group than isolated IGT group and mean
BMI of isolated IFG group was higher than isolated IGT
group both within the normal range (BMI < 25). Thus,
both decreased insulin sensitivity and decreased early-phase
insulin secretory capacity play roles to elevate FPG levels but
decreased insulin sensitivity in IFG subjects with higher BMI
than isolated IGT has stronger effect on elevation of FPG
levels than that of IGT subjects.
Decreased insulin secretory capacity had a stronger effect
on 2 h PG elevation in the studies of Japanese, Korean, and
Chinese subjects [3, 4, 35], while insulin resistance had a
stronger involvement in 2 h PG elevation in other studies
in Caucasian, Pima Indian, American, and Finnish studies
[1, 2, 21, 36]. BMI of Japanese patients with type 2 diabetes
shows only a little elevation (mean BMI was 23.1 kg/m2)
from normal subjects (mean BMI: 22.7 kg/m2) in contrast
with high BMI of Caucasian patients with type 2 diabetes
(mean BMI: 29.4 kg/m2) [37]. Similar to Japanese, East-Asian
patients with type 2 diabetes exhibited stronger association of
insulin secretory capacity with glucose intolerance without
morbid obesity [38]. There are ethnic differences in the
contribution of insulin secretory capacity and insulin resis-
tance to plasma glucose elevation and glucose intolerance as
reported previously [3, 30, 39]. Further studies are required
to establish whether similar results are observed in the other
ethnic populations.
5. Conclusions
We have elucidated that isolated IGT has lower early-phase
insulin secretory capacity than isolated IFG and isolated IFG
has lower insulin sensitivity than isolated IGT.
Two-hour PG levels in isolated IGT group were strongly
associated with decreased early-phase insulin secretory
capacity. FPG levels in isolated IFG group were strongly
associated with decreased insulin sensitivity and nextly with
decreased early-phase insulin secretory capacity. Further
studies are necessary to elucidate a strict causal relationship
in a cohort study. The observation in the present study
could be helpful for the prevention and treatment under
the consideration of each individual’s pathophysiology and
phenotype in the early stage development of type 2 diabetes.
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